Pelvic mass associated with raised CA 125 for benign condition: A case report

World Journal of Surgical Oncology

Volumn 8, Issue , 2010, Pages

  Asher, Viren ^a   Hammond, Robert ^b   Duncan, Tim J ^c  

^a ROYAL DERBY HOSPITAL   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CA 125 ANTIGEN;

ADNEXA DISEASE; ADNEXA MASS; ADULT; APPENDECTOMY; ARTICLE; CASE REPORT; CHLAMYDIASIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; HYDROSALPINX; ILIAC FOSSA PAIN; LAPAROTOMY; OVARY CYST; OVARY TERATOMA; PAIN; PELVIC INFLAMMATORY DISEASE; PELVIS; PELVIS PAIN SYNDROME; PERITONEAL BIOPSY; SALPINGITIS; SALPINGOOOPHORECTOMY; TERATOMA; TRANSVAGINAL ECHOGRAPHY; BLOOD; DIFFERENTIAL DIAGNOSIS; OVARY TUMOR; PATHOLOGY;

ADULT; CA-125 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; OVARIAN CYSTS; OVARIAN NEOPLASMS; PELVIC INFLAMMATORY DISEASE; TERATOMA; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 77950815421     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-8-28     Document Type: Article

References (18)

1. Cancer Research 2005. , http://info.cancerresearchuk.org
2. DeVita VTHS, Rosenberg SA. Principles and Practice of Oncology. 1982, Philadelphia: JB Lippioncott, KR Perez CA, Young RC, 1982.
3. Westhoff C. Ovarian cancer. Annu Rev Public Health 1996, 17:85-96. 10.1146/annurev.pu.17.050196.000505, 8724217.
4. Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983, 309(15):883-7.
5. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981, 68(5):1331-7. 10.1172/JCI110380, 370929, 7028788.
6. Jacobs I, Bast RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989, 4(1):1-12.
7. Malkasian GD, Knapp RC, Lavin PT, Zurawski VR, Podratz KC, Stanhope CR, Mortel R, Berek JS, Bast RC, Ritts RE. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988, 159(2):341-6.
8. Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988, 72(1):23-7.
9. Nolen B, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol
10. Togashi K. Ovarian cancer: the clinical role of US, CT, and MRI. Eur Radiol 2003, 13(Suppl 4):L87-104. 10.1007/s00330-003-1964-y, 15018172.
11. Jeong YY, Outwater EK, Kang HK. Imaging evaluation of ovarian masses. Radiographics 2000, 20(5):1445-70.
12. Balan P. Ultrasonography, computed tomography and magnetic resonance imaging in the assessment of pelvic pathology. Eur J Radiol 2006, 58(1):147-55. 10.1016/j.ejrad.2005.10.002, 16289430.
13. Liu J, Xu Y, Wang J. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis of ovarian carcinoma. Eur J Radiol 2007, 62(3):328-34. 10.1016/j.ejrad.2007.02.040, 17433597.
14. Risum S, Høgdall C, Loft A, Berthelsen AK, Høgdall E, Nedergaard L, Lundvall L, Engelholm SA. The diagnostic value of PET/CT for primary ovarian cancer--a prospective study. Gynecol Oncol 2007, 105(1):145-9. 10.1016/j.ygyno.2006.11.022, 17229460.
15. Ruibal A, Encabo G, Martinéz-Miralles E, Murcia C, Capdevila JA, Salgado A, Martinéz-Vasquéz JM. CA 125 seric levels in non malignant pathologies. Bull Cancer 1984, 71(2):145-6.
16. Halila H, Stenman UH, Seppala M. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer 1986, 57(7):1327-9. 10.1002/1097-0142(19860401)57:7<1327::AID-CNCR2820570713>3.0.CO;2-Z, 3456253.
17. Paavonen J, Miettinen A, Heinonen PK, Aaran RK, Teisala K, Aine R, Punnonen R, Laine S, Kallioniemi OP, Lehtinen M. Serum CA 125 in acute pelvic inflammatory disease. Br J Obstet Gynaecol 1989, 96(5):574-9.
18. Jacobs IJ, Skates S, Davies AP, Woolas RP, Jeyerajah A, Weidemann P, Sibley K, Oram DH. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 1996, 313(7069):1355-8. 2352927, 8956699.